Microbiome and atherosclerosis: hype or future therapeutic target?
Abstract From 2010 to 2025, evidence increasingly identifies the gut microbiome, microbial dysbiosis, trimethylamine-N-oxide (TMAO), and short-chain fatty acids (SCFAs) as modulators of atherosclerosis and cardiovascular disease. We conducted a narrative review of literature retrieved from PubMed, Scopus, and the Clini...